Encapsulation of an EP67-conjugated CTL peptide vaccine in nanoscale biodegradable particles increases the efficacy of respiratory immunization and affects the magnitude and memory subsets of vaccine-generated mucosal and systemic CD8(+) T cells in a diameter-dependent manner

Documenti analoghi

• Surface conjugation of EP67 to biodegradable nanoparticles increases the generation of long-lived mucosal and systemic memory T-cells by encapsulated protein vaccine after respiratory immunization and subsequent T-cell-mediated protection against respiratory infection
  di: Tallapaka, Shailendra B., et al.
  Pubblicazione: (2019)
• Preliminary evidence that the novel host-derived immunostimulant EP67 can act as a mucosal adjuvant
  di: Karuturi, Vamsi K., et al.
  Pubblicazione: (2015)
• Viral Vaccines and CTL Response
  di: Woolard, Stacie N., et al.
  Pubblicazione: (2010)
• Targeted Amino Acid Substitution Overcomes Scale-Up Challenges with the Human C5a-Derived Decapeptide Immunostimulant EP67
  di: Alshammari, Abdulraman M., et al.
  Pubblicazione: (2020)
• BIOMECHANICAL REMODELING OF BIODEGRADABLE SMALL-DIAMETER VASCULAR GRAFTS IN SITU
  di: T. V. Glushkova, et al.
  Pubblicazione: (2016-06-01)